Comparison of amphotericin B lipid complex with amphotericin B and SCH 39304 in the treatment of murine coccidioidal meningitis.
To assess the efficacy of amphotericin B lipid complex (ABLC) in the treatment of coccidioidal meningitis, we compared a wide range of doses (0.35-15 mg kg-1, intravenously (IV)) of ABLC with amphotericin B deoxycholate (AmB) (0.3-7 mg kg-1, intraperitoneally (IP)) and (IV) and a new triazole, SCH 39304 (SCH), in an experimental murine model. Survival data showed high dose ABLC to be of equal efficacy to IV and high dose IP AmB and SCH. Quantitative studies confirmed this outcome. No acute toxicity with ABLC, at the doses employed, was found. We conclude that ABLC is effective in the treatment of murine coccidioidal meningitis.
Allendoerfer
R
R
Department of Medicine, University of Texas Health Science Center, San Antonio 78242.
Yates
R R
RR
Sun
S H
SH
Graybill
J R
JR
D000666:Amphotericin B / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D003047:Coccidioidomycosis / Q000188:drug therapy*; D004337:Drug Carriers; D008081:Liposomes; D016921:Meningitis, Fungal / Q000188:drug therapy*; D051379:Mice; D014230:Triazoles / Q000627:therapeutic use*
D000935:Antifungal Agents; D004337:Drug Carriers; D008081:Liposomes; D014230:Triazoles; C056513:Sch 39304; D000666:Amphotericin B